Tenderwize
Back to tender search

Open House Originale Rabattverträge 2025-13 - Fluticason, Umeclidinium, Vilanterol (Wirkstoffkombination)

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2027 · 285 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-13 - Fluticason, Umeclidinium, Vilanterol (Wirkstoffkombination)

60/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

60 / 100

Complexity

25 / 100

Risk factors

If the patent or market exclusivity expires before the contract end, the contract terminates automatically at the end o...

Submission is only possible via email (with QES) or postal mail. No electronic submission via portal.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of discount agreements (Rabattverträge) under § 130c SGB V for the supply of Fluticason, Umeclidinium, Vilanterol combination products.
  • Agreements are open to all qualified pharmaceutical entrepreneurs on uniform terms.
Show full summary

Techniker Krankenkasse (TK) and other health insurances (HEK, hkk) are offering open house discount agreements for the drug combination Fluticason, Umeclidinium, Vilanterol. Any eligible pharmaceutical entrepreneur can join under uniform conditions with no exclusivity. The contract runs for a maximum of 24 months until 31 May 2027. No estimated value is provided.

Risks

If the patent or market exclusivity expires before the contract end, the contract terminates automatically at the end o...

Submission is only possible via email (with QES) or postal mail. No electronic submission via portal.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG.
  • Must have a valid marketing authorization for the specific medicinal product combination in Germany.

Administrative

  • Must submit a self-declaration (Eigenerklärung) regarding authorization and reliability (Anlage 4 zum Vertrag).

Requirements may be incomplete.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open House Originale Rabattverträge 2025-13 - Fluticason, Umeclidinium, Vilanterol (Wirkstoffkombination)

Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Fluticason, Umeclidinium, Vilanterol zu schließen.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

May 2025 - May 2027

Category

Pharmaceutical products

Procurement Details

Publication date
16 Apr 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
252511-2025

Documents (1)

Similar tenders